Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:6397-6397.

Impact of epidural analgesia on the systemic biomarker response after hepatic resection

Diego Vicente, Miguel Patino, Rebecca Marcus, Heather Lillmoe, Preparim Limani, Timothy Newhook, Andy Lee, Ching-Wei Tzeng, Yun Segraves-Chun, David Tweardy, Vijaya Gottumukkala, Jean-Nicolas Vauthey, Thomas Aloia and Juan P. Cata _

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:584-594. https://doi.org/10.18632/oncotarget.26549

Metrics: PDF 1365 views  |   Full Text 1771 views  |   ?  


Diego Vicente1,2, Miguel Patino2,4, Rebecca Marcus1, Heather Lillmoe1, Preparim Limani1, Timothy Newhook1, Andy Lee1, Ching-Wei Tzeng1, Yun Segraves-Chun1, David Tweardy3, Vijaya Gottumukkala4, Jean-Nicolas Vauthey1, Thomas Aloia1 and Juan P. Cata2,4

1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA

3Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence to:

Juan P. Cata, email: [email protected]

Keywords: analgesia; epidural; cytokines

Received: October 09, 2018     Accepted: December 22, 2018     Published: January 15, 2019


Background: Perioperative inflammation is associated with poor oncologic outcomes. Regional analgesia has been shown mitigate some of these inflammatory changes and be associated with better oncologic outcomes in patients with hepatic malignancies. The mechanism for this effect, however, remains unclear. The authors sought to compare systemic biomarker concentrations in a comprehensive and oncologically relevant panel in the perioperative setting between patients undergoing thoracic epidural analgesia (TEA) and intra-venous patient- controlled analgesia (IV-PCA) for resection of hepatic metastatic disease.

Results: Clinicopathologic variables and baseline biomarkers were similar between TEA (n = 46) and IV-PCA (n = 16) groups. Of the biomarkers which were significantly changed from baseline, there was a lower fold change from baseline in the TEA patients compared to IV-PCA including IL-6 (13.5vs19.1), MCP-1 (1.9vs3.0), IL-8 (2.4vs3.0), and Pentraxin-3 (10.8vs15.6). Overall decreased systemic concentrations of TGFb signaling were noted in TEA patients on POD1 TGFb3 (243.2 vs. 86.0, p = 0.005), POD3 TGFb1 (6558.0 vs. 2063.3, p = 0.004), POD3 TGFb2 (468.3 vs. 368.9, p = 0.036), POD3 TGFb3 (132.2 vs. 77.8, p = 0.028), and POD5 TGFb3 (306.5 vs. 92.2, p = 0.032). POD1 IL-12p70 concentrations were significantly higher in TEA patients (8.3 vs. 1.6, p = 0.024).

Conclusion: Epidural analgesia damped the postoperative inflammatory response and systemic immunosuppressive signaling, as well as promoted Th1 systemic signaling early in the post-operative period after hepatic resection for metastatic disease. These differences elaborate on known mechanisms for improved oncologic outcomes with regional anesthesia, and may be considered for biomarker monitoring of effective regional anesthesia in oncologic surgery.

Materials and Methods: Patient data, including clinicopathologic variables were collected for this study from the database of a randomized controlled trial comparing perioperative outcomes in patients undergoing hepatic resection with TEA vs. IV-PCA. Patients undergoing resection for metastatic disease were selected for this study. Plasma concentrations (pg/mL) of well-studied biomarkers (IL-1b/2/4/5/6/7/8/10/12p70/13/17, MCP-1 IFNγ, TNFα, MIP-1b, GM-CSF, G-CSF, VEGF, Resistin, TGFb1, TGFb2, and TGFb3), as well as novel perioperative markers (CXCL12, CXCL10, Omentin-1, sLeptin R, Vaspin, Pentraxin-3, Galactin-3, FGF-23, PON-1, FGF-21) were measured preoperatively, and on postoperative day (POD)1, POD3, and POD5 using multiplex bead assays. Clinicopathologic variables and perioperative variations in these biomarkers were compared between TEA vs IV-PCA groups.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26549